Buserelin treatment of advanced prostatic cancer: a phase II study.
From August 1986 to September 1988, 76 eligible patients with advanced prostatic carcinoma, measurable or evaluable disease, no previous hormonal treatment, were treated with Buserelin at a dosage of 500 micrograms every 8 h for 7 days, followed by 400 micrograms intranasally three times a day. No concomitant antiandrogens were administered. In the 63 evaluable patients (11 patients not yet evaluable because of short treatment time, two lost to follow-up), three complete remissions, 28 partial remissions, 30 stable disease and two progressions were obtained (National Prostatic Cancer Project criteria). Median duration of response was 55+ weeks. Side effects were modest, mostly related to the endocrinological effects of Buserelin. Transient increase in serum testosterone levels was found in 37% of the evaluable patients, but transitory 'flare-up' was present in seven patients only. With a median follow-up time of 11.5 months, median survival has not been reached. In conclusion, this study confirmed the activity of Buserelin and the feasibility of its middle-term administration.
Veronesi
A
A
Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
Lo Re
G
G
Dal Bo
V
V
Magri
M D
MD
Della Valentina
M
M
Talamini
R
R
Merlo
A
A
Francini
M
M
Monfardini
S
S
D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary; D002064:Buserelin / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction
D002064:Buserelin